Skip to content

Investigation of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients

Phase II Pilot Randomized-Controlled Trial for the Investigation of the Preliminary Efficacy of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05163899
Acronym
OCCULT
Enrollment
20
Registered
2021-12-20
Start date
2022-05-19
Completion date
2027-12-01
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Occult Spina Bifida, Spina Bifida Occulta, Tethered Cord, Tethered Cord Syndrome

Keywords

tethered cord, occult, filum terminale, tight filum

Brief summary

The investigators hypothesize that surgical release of the filum terminale (strand of fibrous tissue at the end of the spinal cord) is a more efficacious treatment option for symptomatic relief than medical management in subjects with Occult Tethered Cord Syndrome (OTCS) and that the risks do not outweigh the benefit profile.

Detailed description

This is a phase II pilot randomized-controlled, single-site trial to determine if surgical untethering of the filum terminale is more effective, preliminarily, than medical management as a treatment option for OTCS. Subjects will be randomized to one of two arms: surgical untethering or medical management only. Symptom improvement and adverse events will be assessed and recorded for 1 year from initiation of treatment. After a minimum of 1 year, subjects who were randomized to the medical management arm may cross over to the surgical arm if the PI deems it is in the subject's best interest to do so. The exploratory hypothesis is that surgery for OTCS is both safe and more effective than medical management at relieving the symptoms of OTCS.

Interventions

PROCEDURERelease of filum terminale

Surgery will be offered to section the filum terminale

Sponsors

Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

For a surgical vs non-surgical trial, the investigator can not be masked thus only the evaluators will be unaware of the arm.

Intervention model description

Subjects will be randomized to one of two arms: surgical untethering or medical management only. Symptom improvement and adverse events will be assessed and recorded for 1 year from initiation of treatment. After a minimum of 1 year, subjects who were randomized to the medical management arm may cross over to the surgical arm if the PI deems it is in the subject's best interest to do so.

Eligibility

Sex/Gender
ALL
Age
2 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male or female ≥ 2 and \< 80 years of age. * Refractory to medical management of symptoms for at least 1 year. * Documentation of OTCS, as defined by a total score of at least 30 on the following scale: OCCULT Grading Scale (Score 0-100) Orthopedic Abnormality: 0-15; Central Nervous System Dysfunction: 0-25; Cutaneous Stigmata: 0-10; Urological or Bowel Dysfunction: 0-25; Lumbosacral Anatomy: 0-15; Tissue Integrity Disorder: 0-10.

Exclusion criteria

* Subjects \< 2 or \> 80 years of age. * Radiographically identified tethered cord, as defined by any of the following: * A low-lying conus (at or below the L2-3 disc space) * A thickened filum (\>2 mm) * Fat in the filum or lipoma * Distinct adhesion or tethering. * A history of Meningocele manqué or Myelomeningocele. * Cutaneous markings of dermal sinus tract. * History of prior surgery on the lumbar spine. * History of prior surgery for spinal dysraphism. * History of prior infection or autoimmune condition of the central nervous system.

Design outcomes

Primary

MeasureTime frameDescription
Change in symptoms related to tethered cord, as measured by the OCCULT ScaleBaseline, 1 yearCombination of neurologic, urologic, orthopedic, and cutaneous assessments. The OCCULT Scale is from 0-100, with 0 being none of the listed signs/symptoms present and 100 being all listed signs/symptoms present with maximum severity.

Secondary

MeasureTime frameDescription
Change in urologic incontinence scoreBaseline, 1 yearScore is measured by the International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form. The minimum score is 0 and the maximum score is 21. The higher the score, the more severe the urinary incontinence symptoms and/or effect of symptoms on quality of life.
Change in fecal incontinence scoreBaseline, 1 yearScore is measured by the Rapid Assessment Faecal Incontinence Score. The minimum score is 0 and the maximum score is 20. The higher the score, the more severe the fecal incontinence symptoms and/or effect of symptoms on quality of life.
Number of patients who cross over1 year
Percent of patients with a decrease in anticholinergic medications at 1 year post-surgery1 yearFor patients who presented with urological symptoms
Number of intra-operative findings that are discordant with MRI interpretationsIntraoperativeTo examine whether there is a limitation in MRI in identifying pathology that is identified at the time of surgery

Countries

United States

Contacts

CONTACTCynthia Nguyen
cyn4002@med.cornell.edu(212) 746-1788
CONTACTJeffrey Greenfield, MD, PhD
jpgreenf@med.cornell.edu(212) 746-2363
PRINCIPAL_INVESTIGATORJeffrey Greenfield, MD, PhD

Weill Medical College of Cornell University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026